These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 29954243)

  • 1. Evaluation of Meropenem Extended Versus Intermittent Infusion Dosing Protocol in Critically Ill Patients.
    Ahmed N; Jen SP; Altshuler D; Papadopoulos J; Pham VP; Dubrovskaya Y
    J Intensive Care Med; 2020 Aug; 35(8):763-771. PubMed ID: 29954243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.
    Chytra I; Stepan M; Benes J; Pelnar P; Zidkova A; Bergerova T; Pradl R; Kasal E
    Crit Care; 2012 Jun; 16(3):R113. PubMed ID: 22742765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III.
    Lipman J; Brett SJ; De Waele JJ; Cotta MO; Davis JS; Finfer S; Glass P; Knowles S; McGuinness S; Myburgh J; Paterson DL; Peake S; Rajbhandari D; Rhodes A; Roberts JA; Shirwadkar C; Starr T; Taylor C; Billot L; Dulhunty JM
    Crit Care Resusc; 2019 Mar; 21(1):63-68. PubMed ID: 30857514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics.
    Chen M; Buurma V; Shah M; Fahim G
    Am J Health Syst Pharm; 2019 Sep; 76(18):1383-1394. PubMed ID: 31505562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study.
    Zhao HY; Gu J; Lyu J; Liu D; Wang YT; Liu F; Zhu FX; An YZ
    Chin Med J (Engl); 2017 May; 130(10):1139-1145. PubMed ID: 28485312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials.
    Roberts JA; Abdul-Aziz MH; Davis JS; Dulhunty JM; Cotta MO; Myburgh J; Bellomo R; Lipman J
    Am J Respir Crit Care Med; 2016 Sep; 194(6):681-91. PubMed ID: 26974879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial.
    Dulhunty JM; Brett SJ; De Waele JJ; Rajbhandari D; Billot L; Cotta MO; Davis JS; Finfer S; Hammond NE; Knowles S; Liu X; McGuinness S; Mysore J; Paterson DL; Peake S; Rhodes A; Roberts JA; Roger C; Shirwadkar C; Starr T; Taylor C; Myburgh JA; Lipman J;
    JAMA; 2024 Aug; 332(8):629-637. PubMed ID: 38864155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis.
    Pařízková RČ; Martínková J; Havel E; Šafránek P; Kaška M; Astapenko D; Bezouška J; Chládek J; Černý V
    Crit Care; 2021 Jul; 25(1):251. PubMed ID: 34274013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
    Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
    O'Jeanson A; Larcher R; Le Souder C; Djebli N; Khier S
    Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):695-705. PubMed ID: 34403127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?
    Esteve-Pitarch E; Gumucio-Sanguino VD; Cobo-Sacristán S; Shaw E; Maisterra-Santos K; Sabater-Riera J; Pérez-Fernandez XL; Rigo-Bonnin R; Tubau-Quintano F; Carratalà J; Colom-Codina H; Padullés-Zamora A
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):527-538. PubMed ID: 34131869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
    Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial.
    Monti G; Bradic N; Marzaroli M; Konkayev A; Fominskiy E; Kotani Y; Likhvantsev VV; Momesso E; Nogtev P; Lobreglio R; Redkin I; Toffoletto F; Bruni A; Baiardo Redaelli M; D'Andrea N; Paternoster G; Scandroglio AM; Gallicchio F; Ballestra M; Calabrò MG; Cotoia A; Perone R; Cuffaro R; Montrucchio G; Pota V; Ananiadou S; Lembo R; Musu M; Rauch S; Galbiati C; Pinelli F; Pasin L; Guarracino F; Santarpino G; Agrò FE; Bove T; Corradi F; Forfori F; Longhini F; Cecconi M; Landoni G; Bellomo R; Zangrillo A;
    JAMA; 2023 Jul; 330(2):141-151. PubMed ID: 37326473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal Dosing of Meropenem in a Small Cohort of Critically Ill Children Receiving Continuous Renal Replacement Therapy.
    Tan WW; Watt KM; Boakye-Agyeman F; Cohen-Wolkowiez M; Mok YH; Yung CF; Chan YH
    J Clin Pharmacol; 2021 Jun; 61(6):744-754. PubMed ID: 33314163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.
    Abdul-Aziz MH; Sulaiman H; Mat-Nor MB; Rai V; Wong KK; Hasan MS; Abd Rahman AN; Jamal JA; Wallis SC; Lipman J; Staatz CE; Roberts JA
    Intensive Care Med; 2016 Oct; 42(10):1535-1545. PubMed ID: 26754759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of 3-hour and 30-minute infusion regimens for meropenem in patients with hospital acquired pneumonia in intensive care unit: a randomized controlled clinical trial].
    Wang Z; Shan T; Liu Y; Ding S; Li C; Zhai Q; Chen X; Du B; Li Y; Zhang J; Wang H; Wu D
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2014 Sep; 26(9):644-9. PubMed ID: 25230866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.
    Dulhunty JM; Roberts JA; Davis JS; Webb SA; Bellomo R; Gomersall C; Shirwadkar C; Eastwood GM; Myburgh J; Paterson DL; Starr T; Paul SK; Lipman J;
    Am J Respir Crit Care Med; 2015 Dec; 192(11):1298-305. PubMed ID: 26200166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
    Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous infusion versus intermittent administration of meropenem in critically ill patients (MERCY): A multicenter randomized double-blind trial. Rationale and design.
    Monti G; Galbiati C; Toffoletto F; Calabrò MG; Colombo S; Ferrara B; Giardina G; Lembo R; Marzaroli M; Moizo E; Mucci M; Pasculli N; Plumari VP; Scandroglio AM; Tozzi M; Momesso E; Boffa N; Lobreglio R; Montrucchio G; Guarracino F; Benedetto U; Biondi-Zoccai G; D'Ascenzo F; D'Andrea N; Paternoster G; Ananiadou S; Ballestra M; De Sio A; Pota V; Cotoia A; Della Selva A; Bruni A; Iapichino G; Bradić N; Corradi F; Gemma M; Nogtev P; Petrova M; Agrò FE; Cabrini L; Forfori F; Likhvantsev V; Bove T; Finco G; Landoni G; Zangrillo A;
    Contemp Clin Trials; 2021 May; 104():106346. PubMed ID: 33684595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes of Extended Versus Intermittent Infusion of Piperacillin/Tazobactam in Critically Ill Patients: A Prospective Clinical Trial.
    Fan SY; Shum HP; Cheng WY; Chan YH; Leung SM; Yan WW
    Pharmacotherapy; 2017 Jan; 37(1):109-119. PubMed ID: 27888542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.